TD Cowen analyst Josh Jennings maintains $Boston Scientific (BSX.US)$ with a buy rating, and maintains the target price at $100.
According to TipRanks data, the analyst has a success rate of 54.6% and a total average return of 4.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Boston Scientific (BSX.US)$'s main analysts recently are as follows:
Boston Scientific has presented a quarter that exceeded forecasts on all fronts, in spite of already lofty anticipations. Nonetheless, the company's shares are currently experiencing pressure due to the temporary halt of the AVANT GUARD clinical trial, which is investigating Farapulse in a new patient cohort. It is essential to note that the affected patient segment is not currently receiving treatment, that there are certain observations under evaluation, and that the enrollment for the study is anticipated to recommence shortly.
Boston Scientific's Q3 outcomes were characterized as 'impressive,' coinciding with an elevation in management's 2024 guidance, now forecasting an exit with +15% organic sales growth. The company's stock experienced a decline following a temporary halt in an EP trial, AVANTGUARD. However, this reaction is considered to be exaggerated when taking into account insights from key opinion leaders.
The setback in the AVANT Guard trial is not associated with a mortality event or triggered by regulatory authority, and the momentum for global Farapulse is considered sustainable over the medium term. It is believed that the recent decline in Boston Scientific shares offers an attractive entry point for investors.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
TD Cowen分析師Josh Jennings維持$波士頓科學 (BSX.US)$買入評級，維持目標價100美元。
根據TipRanks數據顯示，該分析師近一年總勝率為54.6%，總平均回報率為4.5%。
此外，綜合報道，$波士頓科學 (BSX.US)$近期主要分析師觀點如下：
波士頓科學公司提出的季度報告在各方面超出了預期，儘管預期已經很高。然而，由於AVANt GUARD臨床試驗暫時停止，目前公司股價承受壓力，該臨床試驗正在研究Farapulse在新的患者隊列中的應用。重要的是要注意，受影響的患者群體目前未接受治療，還有某些觀察結果正在評估中，預計研究的招募將很快重新開始。
波士頓科學的第三季度業績被描述爲「令人印象深刻」，並與管理層2024年預期指引的提高相一致，現在預測退出時有+15%的有機銷售增長。公司股價在一項EP試驗AVANTGUARD暫停後出現下跌。然而，考慮到重要意見領袖的見解，此反應被認爲是誇大的。
AVANt Guard試驗的挫折不是由死亡事件引起的，也不是由監管機構觸發的，全球Farapulse的增勢被認爲在中期內可持續。人們相信，波士頓科學股價最近的下跌爲投資者提供了一個有吸引力的入場點。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
